Clinical trials: Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.
- Trial name
- PROMISS-DKD (NCT06962098)
- Testing
- Isuzinaxib
- Where
- 20 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Aptabio Therapeutics, Inc.
Diabetic Nephropathy
Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)
Current expert opinion based consensus guidelines recommend usage of α-Keto analogues of essential amino acids in the diet of diabetic nephropathy patients, along with restricted protein diets.
- Trial name
- NCT00363987
- Testing
- Ketosteril®, diabetic diet
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Fresenius Kabi
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Diabetic Nephropathy
Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy
To determine the effects of three different doses of bardoxolone methyl administered orally on the kidney function (glomular filtration rate) in patients with diabetic nephropathy.
- Trial name
- NCT00664027
- Testing
- RTA 402 (Bardoxolone Methyl)
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biogen
Hypertensive Nephropathy, Auto Immune Disorders
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages.
- Conditions
- Hypertensive Nephropathy, Auto Immune Disorders, Chronic Kidney Disease, Chronc Kidney Disease Stage 5
- Trial name
- ACE Reno (NCT07187713)
- Testing
- ACE Reno
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Ace Cells Lab Limited
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Olmesartan Medoxomil and Diabetic Nephropathy
Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Proteinuria, Renal Disease
- Trial name
- NCT00362960
- Testing
- Olmesartan medoxomil, Losartan
- Where
- 27 sites in Czechia, Estonia and 5 more
- Volunteers
- 300 people
- Sponsor
- Sankyo Pharma Gmbh
Non-diabetic Nephropathy With Hypertension
ARIA (Atacand Renoprotection In NephropAthy Pt.)
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g…
- Trial name
- PCR (NCT00573430)
- Testing
- Candesartan Cilexetil, Candesartan Cilexetil 32mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Hypertension, Diabetes Mellitus, Type 2
DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril
To compare the renal consequences of two different approaches to blocking the renin angiotensin system in subjects with hypertension and concurrent Type II diabetes mellitus and diabetic nephropathy.
- Trial name
- NCT00274118
- Testing
- telmisartan, enalapril
- Where
- 37 sites in Denmark, Finland and 4 more
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout.
- Trial name
- UPWARD (NCT02327754)
- Testing
- Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Non-diabetic Nephropathy
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.
- Trial name
- ARIA (NCT01302899)
- Testing
- Aliskiren, Hydrochlorothiazide (HCTZ), Ramipril
- Where
- 2 sites in Netherlands
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Anemia, Diabetes, Kidney Disease, Chronic, Hypertension
Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan
The purpose of this study is to evaluate the prevalence of CKD-related anemia at an early stage through screening of high-risk patients in Pakistan at the level of physicians, cardiologists, and diabetologists.
- Trial name
- NCT02444845
- Where
- 3 sites in Pakistan
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Diabetic Nephropathy
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
Phase 2 clinical study to evaluate of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy
- Trial name
- NCT01935167
- Testing
- DW1029M 600mg, DW1029M 1200mg
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Hypertension, Early Diabetic Nephropathy
Antialbuminuric Effects of Valsartan and Lisinopril
Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.
- Trial name
- NCT00171600
- Testing
- VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
This study is to assess the effect of renal function on the efficacy and safety of ASP1941 in type 2 diabetic patients with mild to moderate renal impairment.
- Trial name
- NCT01316094
- Testing
- ASP1941
- Where
- 8 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Diseases
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
- Trial name
- NCT04990427
- Testing
- CLBS201
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Lisata Therapeutics, Inc.
Diabetic Kidney Disease, Type 2 Diabetes
Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes
The study is a 16-week multicenter, randomized, double-blind, placebo-controlled, parallel-designed Phase II clinical study. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with diabetic…
- Trial name
- SOLID-DKD (NCT06415214)
- Testing
- HRS-7535
- Where
- China
- Volunteers
- 281 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.